Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More

Terry Chrisomalis Investing Group Leader Follow Summary Nektar Therapeutics is downgraded from Strong Buy to Hold due to safety concerns with REZPEG despite positive efficacy data. Phase 2b REZOLVE-AA study showed 63% off-treatment durability but 91.7% injection site reactions, raising doubts about REZPEG's market potential in AA. NKTR maintains a strong cash position [$1.02B as of June 2026], sufficient to fund operations into Q3 2028, reducing near-term dilution risk. Phase 3 ZENITH AD and AA programs are progressing, but high injection site reactions/upper respiratory tract infections and uncertain regulatory outcomes temper the NKTR investment thesis. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Thitaporn Yaroteak/iStock via Getty Images The last time I spoke about Nektar Therapeutics ( NKTR ) it was with a Seeking Alpha article entitled " Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming ." With respect This article was written by Terry Chrisomalis 15.19K Followers Follow Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.